Trial Profile
A Phase 1b/2a Multicenter Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 29 Jun 2023
Price :
$35
*
At a glance
- Drugs Idronoxil (Primary)
- Indications Advanced breast cancer; Male breast cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Noxopharm
- 28 Jun 2023 This trial has been completed in Hungary (Date of the global end of the trial: 7 June 2023).
- 12 Jun 2023 Status changed from active, no longer recruiting to discontinued due to slow recruitment.
- 27 Apr 2023 Planned End Date changed from 28 Feb 2024 to 31 Aug 2023.